Athira Pharma (NASDAQ:ATHA) Announces Earnings Results

Athira Pharma (NASDAQ:ATHAGet Rating) issued its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01), MarketWatch Earnings reports.

ATHA opened at $8.28 on Friday. The business’s fifty day simple moving average is $11.01 and its 200-day simple moving average is $11.72. Athira Pharma has a 12-month low of $7.56 and a 12-month high of $23.64.

In other Athira Pharma news, Director Kelly A. Romano purchased 8,000 shares of Athira Pharma stock in a transaction dated Thursday, March 31st. The stock was acquired at an average price of $13.11 per share, for a total transaction of $104,880.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 14.90% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. bought a new position in shares of Athira Pharma in the 3rd quarter worth $112,000. Metropolitan Life Insurance Co NY grew its stake in Athira Pharma by 42.9% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 10,300 shares of the company’s stock valued at $134,000 after purchasing an additional 3,091 shares during the last quarter. Bank of America Corp DE raised its holdings in Athira Pharma by 56.3% in the second quarter. Bank of America Corp DE now owns 16,749 shares of the company’s stock worth $172,000 after purchasing an additional 6,036 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Athira Pharma by 85.7% during the fourth quarter. MetLife Investment Management LLC now owns 13,703 shares of the company’s stock valued at $179,000 after buying an additional 6,323 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of Athira Pharma by 55.0% in the 4th quarter. Parametric Portfolio Associates LLC now owns 23,882 shares of the company’s stock valued at $311,000 after buying an additional 8,477 shares in the last quarter. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently commented on ATHA shares. Berenberg Bank initiated coverage on shares of Athira Pharma in a report on Thursday, April 21st. They set a “buy” rating and a $33.00 price target on the stock. JMP Securities reissued a “buy” rating and set a $51.00 price target on shares of Athira Pharma in a research note on Friday, March 25th. BTIG Research began coverage on Athira Pharma in a research report on Tuesday. They issued a “buy” rating and a $33.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Athira Pharma from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $29.40.

Athira Pharma Company Profile (Get Rating)

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.

Featured Stories

Earnings History for Athira Pharma (NASDAQ:ATHA)

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.